{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:15:13Z","timestamp":1770815713994,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2004,12,2]],"date-time":"2004-12-02T00:00:00Z","timestamp":1101945600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1007\/s00296-004-0544-z","type":"journal-article","created":{"date-parts":[[2004,12,2]],"date-time":"2004-12-02T03:25:46Z","timestamp":1101957946000},"page":"195-200","source":"Crossref","is-referenced-by-count":17,"title":["Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis"],"prefix":"10.1007","volume":"26","author":[{"given":"Mengu","family":"Sarioglu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cigdem","family":"Tuzun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeliha","family":"Unlu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Canan","family":"Tikiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma","family":"Taneli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. Sami.","family":"Uyanik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,12,2]]},"reference":[{"key":"544_CR1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/BF01880454","volume":"1","author":"Consensus development conference: prophylaxis and treatment of osteoporosis","year":"1991","unstructured":"Consensus development conference: prophylaxis and treatment of osteoporosis (1991) Osteoporos Int 1:114\u2013117","journal-title":"Osteoporos Int"},{"key":"544_CR2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0002-9343(05)80037-3","volume":"98","author":"E Garrett-Connor","year":"1995","unstructured":"Garrett-Connor E (1995) The economic and human costs of osteoporotic fracture. Am J Med 98:3\u20138","journal-title":"Am J Med"},{"issue":"suppl 3","key":"544_CR3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00198-002-1345-4","volume":"14","author":"P Ammann","year":"2003","unstructured":"Ammann P, Rizzoli R (2003) Bone strength and its determinants. Osteoporos Int 14(suppl 3):13\u201318","journal-title":"Osteoporos Int"},{"key":"544_CR4","first-page":"657","volume":"81","author":"K Akesson","year":"2003","unstructured":"Akesson K (2003) New approaches to pharmacological treatment of osteoporosis. Bull World Health Organ 81:657\u2013664","journal-title":"Bull World Health Organ"},{"key":"544_CR5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11926-004-0084-2","volume":"6","author":"SB Cohen","year":"2004","unstructured":"Cohen SB (2004) An update on bisphosphonates. Curr Rheumatol Rep 6:59\u201365","journal-title":"Curr Rheumatol Rep"},{"key":"544_CR6","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","volume":"112","author":"SR Cummings","year":"2002","unstructured":"Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM (2002) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281\u2013289","journal-title":"Am J Med"},{"key":"544_CR7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1359-6446(97)01134-3","volume":"3","author":"J Yates","year":"1998","unstructured":"Yates J, Rodan GA (1998) Alendronate and osteoporosis. Drug Dis Today 3:69\u201378","journal-title":"Drug Dis Today"},{"issue":"suppl I","key":"544_CR8","first-page":"256","volume":"6","author":"M McClung","year":"1996","unstructured":"McClung M, Bensen W, Bologne M (1996) Risedronate treatment of postmenopausal women with low bone mass: preliminary data. Osteoporos Int 6(suppl I):256","journal-title":"Osteoporos Int"},{"key":"544_CR9","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/PL00004152","volume":"7","author":"B Clemmesen","year":"1997","unstructured":"Clemmesen B, Ravn P, Zegels B,Taquet AN, Christiansen C, Reginster JY (1997) A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. Osteoporos Int 7:488\u2013495","journal-title":"Osteoporos Int"},{"key":"544_CR10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral efficacy with risedronate therapy (VERT) study group. Osteoporos Int 11:83\u201389","journal-title":"Osteoporos Int"},{"key":"544_CR11","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis.: a randomized control trial. Vertebral efficacy with Risedronate therapy (VERT) study group. JAMA 282:1344\u20131352","journal-title":"JAMA"},{"key":"544_CR12","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","volume":"333","author":"UA Liberman","year":"1995","unstructured":"Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M (1995) Effect of alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437\u20131443","journal-title":"N Engl J Med"},{"key":"544_CR13","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535\u20131341","journal-title":"Lancet"},{"key":"544_CR14","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","volume":"85","author":"DM Black","year":"2000","unstructured":"Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR (2000) Fracture risk reduction with alendronate in women osteoporosis: the Fracture Intervention Trial : FIT Research Group. J Clin Endocrinol Metab 85:4118\u20134124","journal-title":"J Clin Endocrinol Metab"},{"key":"544_CR15","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.1532-5415.2002.50102.x","volume":"50","author":"S Levis","year":"2002","unstructured":"Levis S, Quandt SA, Thompson D, Scott J, Schneider DL, Ross PD, Black D, Suryawanshi S, Hochberg M, Yates J (2002) Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial. J Am Geratr Soc 50:409\u2013415","journal-title":"J Am Geratr Soc"},{"key":"544_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF03339822","volume":"12","author":"T Schnitzer","year":"2002","unstructured":"Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC, Kaur A, Thompson DE, Yates J, Orloff JJ (2000) Therapeutic equivalence of alendronate 70\u00a0mg once-weekly and alendronate 10\u00a0mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano)12:1\u201312","journal-title":"Aging (Milano)"},{"key":"544_CR17","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1359\/jbmr.2002.17.11.1988","volume":"17","author":"R Rizzoli","year":"2002","unstructured":"Rizzoli R, Greenspan SL, Bone G, Schnitzer TJ, Watts NB, Adami S, Foldes AJ, Roux C, Levine MA, Uebelhart B, Santora AC 2nd, Kaur A, Peverly CA, Orloff JJ (2002) Alendronate Once-Weekly Study Group: Two-year results of once-weekly administration of alendronate 70\u00a0mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 17:1988\u20131996","journal-title":"J Bone Miner Res"},{"key":"544_CR18","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s001980200135","volume":"13","author":"M Fukunaga","year":"2002","unstructured":"Fukunaga M, Kushida K, Kishimoto H, Shiraki M, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H (2002) A comparison of the effect of risedronate and ethidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. Osteoporos Int 13:971\u2013979","journal-title":"Osteoporos Int"},{"key":"544_CR19","first-page":"125","volume":"24","author":"H Ertekin","year":"1999","unstructured":"Ertekin H, Onbasi K, Yaradanakul S (1999) Postmenopozal osteoporozda ethidronat ve alendronat tedavilerinin karsilastirilmasi. Cukurova Universitesi Tip Fakultesi Dergisi 24:125\u2013137","journal-title":"Cukurova Universitesi Tip Fakultesi Dergisi"},{"key":"544_CR20","first-page":"956","volume":"11","author":"O Sahota","year":"2000","unstructured":"Sahota O, Fowler I, Blackwell PJ, Lawson N, Cawte SA, San P, Masud T, Hosking DJ (2000) A comparison of continuous alendronate, cyclical alaendronate and cyclical ethidronate with calcitriol in the treatment of postmenopausal vertebral osteoporosis: a randomized controlled trial. Osteoporos Int 11:956\u2013966","journal-title":"Osteoporos Int"},{"issue":"5","key":"544_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/030079903125002009","volume":"19","author":"D Hosking","year":"2003","unstructured":"Hosking D, Adami S, Felsenberg D Andia JC, Valimaki M, Benhamou L, Reginster JY, Yacik C, Rybak-Feglin A, Petruschke RA, Zaru L, Santora AC (2003) Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomized, placebo-controlled study. Curr Med Res Opin 19(5):1\u201312","journal-title":"Curr Med Res Opin"},{"key":"544_CR22","unstructured":"World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843, Geneva"},{"key":"544_CR23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-002-2011-8","volume":"71","author":"JP Brown","year":"2002","unstructured":"Brown JP, Kendler DL, McClung MR Emkey RD, Adachi JD, Bolognese MA, Li Z, Balske A, Lindsay R. (2002) The efficacy and tolerability of risedronate once a week for a treatment of post-menopausal osteoporosis. Calcif Tissue Int 71:103\u2013111","journal-title":"Calcif Tissue Int"},{"key":"544_CR24","first-page":"40","volume":"101","author":"E Seeman","year":"1999","unstructured":"Seeman E (1999) The antifracture efficacy of alendronate. Int J Clin Pract Suppl 101:40\u201345","journal-title":"Int J Clin Pract Suppl"},{"key":"544_CR25","first-page":"1895","volume":"85","author":"I Fogelman","year":"2000","unstructured":"Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster JY (2000) Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN study group. J Clin Endocrinol Metab 85:1895\u20131900","journal-title":"J Clin Endocrinol Metab"},{"key":"544_CR26","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1210\/jc.2002-020400","volume":"88","author":"NB Watts","year":"2003","unstructured":"Watts NB, Josse RG, Hamdy RC, Hughes RA, Manhart MD, Barton I, Calligeros D, Felsenberg D (2003) Risedronate prevents new vertebral fractures in postmenopausal women at risk. J Clin Endocrinol Metab 88:542\u2013549","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-004-0544-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-004-0544-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-004-0544-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T11:15:17Z","timestamp":1559042117000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-004-0544-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12,2]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["544"],"URL":"https:\/\/doi.org\/10.1007\/s00296-004-0544-z","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12,2]]}}}